Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Peripheral Nervous System Diseases 1Ovarian Neoplasms 1Breast Neoplasms 1

Interventions

Glutamine 2sagopilone 1nicotinamide-beta-riboside 1allantoicase 1Vitamin D 1Vitamin B 6 1Vitamin B 12 1Taxoids 1Tadalafil 1Sirolimus 1Prednisolone 1Paclitaxel 1Minocycline 1Metformin 1Losartan 1Hydroxychloroquine 1G(M1) Ganglioside 1Fatty Acids, Omega-3 1Exercise 1Everolimus 1Etoricoxib 1Ethosuximide 1Epoetin Alfa 1Dietary Supplements 1Dexamethasone 1Cryotherapy 1Bortezomib 1BID protein, human 1Acupuncture Therapy 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Peripheral Nervous System Diseases × allantoicase × Clear all
NCT00751205 2014-10-28

Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Bayer

Phase 2 Completed
150 enrolled
GenitourinaryGynecologic

Ovarian Neoplasms, Peripheral Nervous System Diseases, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡